Mezaki T, Kaji R, Kimura J, Osame M, Mizuno Y, Hirayama K, Maruyama S, Iwata M, Kanazawa I, Kinoshita M
Department of Neurology, Faculty of Medicine, Kyoto University, Japan.
No To Shinkei. 1995 Aug;47(8):749-54.
We studied the clinical effectiveness of botulinum toxin type A for spasmodic torticollis and that for facial spasm by multicenter, non-blinded study. The freeze-dried crystalline botulinum toxin type A (AGN 191622; Allergan Inc., Irvine, CA) was injected into the hyperactive muscles and the clinical course was followed for 22 weeks. Repeated injections were done, if necessary, with an interval of 4 weeks. The toxin was highly effective in both disorders. In spasmodic torticollis, clinical severity improved in 38 (63.3%) and the global improvement was seen in 39 (65.0%) out of 60 patients. Subjective improvement was seen in 56 (93.3%). In facial spasm, 52 (92.9%) out of 56 patients improved after the treatment. Unfavorable reactions, mainly consisting of neck muscle weakness and dysphagia in torticollis and facial weakness in facial spasm, were mostly due to the excessive action of the toxin. They were usually mild and transient. No patients discontinued the trial because of side effects. Botulinum toxin injection is a very useful and safe method for the symptomatic treatment of spasmodic torticollis and facial spasm.
我们通过多中心、非盲法研究，对A型肉毒杆菌毒素治疗痉挛性斜颈和面部痉挛的临床疗效进行了研究。将冻干结晶A型肉毒杆菌毒素（AGN 191622；Allergan公司，加利福尼亚州欧文市）注射到活动亢进的肌肉中，并对临床病程进行了22周的跟踪。如有必要，每隔4周重复注射一次。该毒素对这两种疾病均有高效。在痉挛性斜颈患者中，60例患者中有38例（63.3%）临床严重程度得到改善，39例（65.0%）整体病情好转。56例（93.3%）患者有主观改善。在面部痉挛患者中，56例中有52例（92.9%）治疗后病情好转。不良反应主要包括痉挛性斜颈患者的颈部肌肉无力和吞咽困难以及面部痉挛患者的面部无力，大多是由毒素作用过度所致。这些不良反应通常较轻且为一过性。没有患者因副作用而停止试验。A型肉毒杆菌毒素注射是一种非常有用且安全的治疗痉挛性斜颈和面部痉挛症状的方法。
